Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections

Current Opinion in Pediatrics

Volumn 8, Issue 5, 1996, Pages 531-540

  Schneider, Lynda C ^a   Lester, Mitchell R ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; ASTEMIZOLE; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CETIRIZINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; CYTOKINE; DIPHENHYDRAMINE; EYE DROPS; FLUNISOLIDE; FLUTICASONE; HYDROXYZINE; IMMUNOMODULATING AGENT; IPRATROPIUM BROMIDE; LIPOXYGENASE INHIBITOR; LODOXAMIDE; LORATADINE; NEDOCROMIL SODIUM; NOSE SPRAY; PLACEBO; RECOMBINANT GAMMA INTERFERON; SODIUM CHLORIDE; TACROLIMUS; TERFENADINE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; ZILEUTON;

ADRENAL SUPPRESSION; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; ATOPY; CHILD; CLINICAL TRIAL; FOOD ALLERGY; GROWTH RETARDATION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFANT; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MILK ALLERGY; NEWBORN; PRIORITY JOURNAL; REVIEW; RHINORRHEA; SKIN ATROPHY; TOPICAL DRUG ADMINISTRATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 0029965615     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199610000-00019     Document Type: Review

References (95)

1. Neame R, Berth-Jones J, Kurinczuk J, Graham-Brown R: Prevalence of atopic dermatitis in Leicester: a study of methodology and examination of possible ethnic variation. Br J Dermatol 1995, 132:772-777.
2. Leung DYM: Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol 1995, 96:302-319. This paper highlights several important advances in the immunopathogenesis of AD and nicely links the clinical with the basic science aspects of the disease.
3. Clayton M, Leung DYM, Surs W, Szefler S: Altered glucocorticoid receptor binding in atopic dermatitis. J Allergy Clin Immunol 1995, 96:421-423.
4. Jenney M, Childs C, Mabin D, Beswick M, David T: Oxygen consumption during sleep in atopic dermatitis. Arch Dis Child 1995, 72:144-146.
5. Patel L, Clayton P, Addison G, Price D, David T: Adrenal function following topical steroid treatment in children with atopic dermatitis. Br J Dermatol 1995, 132:950-955.
6. Tan B, Weald D, Strickland I, Friedmann P: Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 1996, 347:15-18.
7. Mabin D, Sykes A, David T: Controlled trial of a few foods diet in severe atopic dermatitis. Arch Dis Child 1995, 73:202-207.
8. Aoyama H, Tabata N, Tanaka M, Uesugi Y, Tagami H: Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol 1995, 133:494-495.
9. Nakagawa H, Etoh T, Ishibahi Y, Higaki Y, Kawashima M, Toril H, Harada S: Tacrolimus ointment for atopic dermatitis. Lancet 1994, 344:883.
10. Latchman Y, Bungy G, Atherton D, Rustin M, Brostoff J: Efficacy of traditional Chinese herbal therapy in vitro: a model system for atopic eczema: inhibition of CD23 expression on blood monocytes. Br J Dermatol 1995, 132:592-598.
11. Collins P, Ferguson J: Narrowband (TL-01) UVB air-conditioned phototherapy for atopic eczema in children. Br J Dermatol 1995, 133:653-667.
12. Musiel J, Milewski M, Undas A, Kopinski P, Duplaga M, Szczeklik A: Interferon-gamma in the treatment of atopic dermatitis: Influence on T-cell activation. Allergy 1995, 50:520-523. Ten patients with severe AD were treated with recombinant interferon-γ. In parallel with clinical improvement, a decrease in activated (CD25+) T cells was found.
13. Crosby I: My skin is only the top layer of the problem. Arch Dermatol 1995, 131:783-785. Anyone who takes care of patients with AD should read this article. Ms. Crosby eloquently explains what our patients may not tell us.
14. Dahl R, Bernhisel-Broadbent J, Scanlon-Holdford S, Sampson H, Lupo M: Sleep disturbances in children with atopic dermatitis. Arch Pediatr Adolesc Med 1995, 149:856-860. Sleep disturbance in AD is a difficult problem that requires significant attention. These authors compared the result of the child sleep behavior scale in 59 children with AD to normative data. This study reviews the disrupted sleep patterns and suggests treatment strategies.
15. Stewart A, Thomas S: Hypnotherapy as a treatment for atopic dermatitis in adults and children. Br J Dermatol 1995, 132:778-783. This article emphasizes the benefit of behavioral approaches in AD.
16. Altintas D, Guneser S, Evliayaoglu N, Yuksel B, Atiei A, Serbest M: A prospective study of cow's milk allergy in Turkish infants. Acta Paediatr 1995, 84:1320-1321.
17. Van Beresteijn E, Meijer G, Schmidt D: Residual antigenicity of hypoallergenic infant formulas and the occurrence of milk specific IgE antibodies in patients with clinical allergy [letter]. J Allergy Clin Immunol 1995, 96:365-374.
18. Restani P, Velona T, Plebani A, Ugazio A, Poiesi C, Muraro A, GAlli C: Evaluation by SDS-PAGE and immunoblotting of residual antigenicity in hydrolysed protein formulas. Clin Exp Allergy 1995, 25:651-658.
19. Isolauri E, Sutas Y, Makinen-Kiljunen S, Oja S, Isosomppi R, Turjanmaa K: Efficacy and safety of hydrolyzed cow milk and amino acid-derived formulas in infants with cow milk allergy. J Pediatr 1995, 127:550-557. Extensively hydrolyzed formulas and an amino acid-derived formula were found to be safe and effective for infants with cow's milk allergy. The group fed an amino acid-derived formula had a trend toward better growth than the hydrolysate group.
20. Hill D, Camercon D, Francis D, Gonzalez-Andaya A, Hosking C: Challenge confirmation of late-onset reactions to extensively hydrolyzed formulas in infants with multiple food protein intolerance. J Allergy Clin Immunol 1995, 96:386-394. Families at times report late-onset reaction to soy and casein hydrolysate formulas. This study documents that late reactions occur and that an amino acid-derived formula is an effective substitute.
21. Iacono G, Carroccio A, Cavataio F, Montalto G, Kazmierska I, Lorello D, Soresi M, Notarbartolo A: Gastroesophageal reflux and cow's milk allergy in infants: a prospective study. J Allergy Clin Immunol 1996, 97:822-827. Gastroesophageal reflux was associated with and probably caused cow's milk allergy in 42% of 204 infants.
22. Zeiger R, Heller S: The development and prediction of atopy in high-risk children: follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance. J Allergy Clin Immunol 1995, 95:1179-1190. This study examines the development of atopy at age 7 years in a cohort of 165 children at high risk for atopy. It provides useful insight into the natrual history of atopic disease and the interactions of genetic and environmental factors in the development of atopy.
23. Saarinen U, Kajosaari M: Breastfeeding as prophylaxis against atopic disease: prospective follow-up study until 17 years old. Lancet 1995, 346:1065-1069. This long-term follow-up study is another reference to support the significant benefits of breast feeding.
24. Price G, Hogan A, Farris A, Burks A, Platts-Mills A, Heymann P: Sensitization (IgE antibody) to food allergens in wheezing infants and children. J Allergy Clin Immunol 1995, 96:266-270.
25. James J, Eigenmann P, Eggleston P, Sampson H: Airway reactivity changes in asthmatic patients undergoing blinded food challenges. Am J Respir Crit Care Med 1996, 153:597-603.
26. Centers for Disease Control: Asthma-United States, 1982-92. MMWR Morb Mortal Wkly Rep 1995, 43:952-955.
27. National Heart, Lung, and Blood Institute: Guidelines for the Diagnosis and Management of Asthma. Bethesda: National Institutes of Health; 1991.
28. National Heart, Lung, and Blood Institute: Global Initiative for Asthma. Bethesda: National Institutes of Health; 1995.
29. Spector S, Nicklas R: Practice parameters for the diagnosis and treatment of asthma. J Allergy Clin Immunol 1995, 96:707-870. This summary statement is a thorough, completely referenced manual addressing most aspects of basic asthma care. It was prepared as a joint effort of the American Academy of Allergy, Asthma, and Immunology, the American College of Allergy, Asthma, and Immunology, and the Joint Council of Allergy, Asthma, and Immunology but is as important for primary care physicians as the guidelines for the diagnosis and management of asthma put forth by the National Heart, Lung, and Blood Institute were 5 years ago.
30. Terr A, Bloch D: Trends in asthma therapy in the United States: 1965-1992. Ann Allergy Asthma Immunol 1996, 76:273-281.
31. Creticos P, Burk J, Smith L, Comp R, Norman P, Findlay S: The use of twice daily nedocromil sodium in the treatment of asthma. J Allergy Clin Immunol 1995, 95:829-836. Nedocromil sodium was released for use in the United States in 1993. Despite its unpleasant taste, twice daily nedocromil sodium is useful for mild and moderate asthmatics. In this study patients who received nedocromil sodium had fewer symptoms and less need for rescue medications than patients treated with placebo. There was no difference in forced expiratory volume in 1 second between groups, but patients in the placebo group used 23% more β-agonists, perhaps artificially diminishing the difference between groups.
32. Rutten-van Molken M, van Doorslaer E, Jansen M, Kerstjens H, Rutten F: Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995, 151:975-982. The costs of asthma care are direct and indirect. Although BDP, 100 mg/d (2 puffs) cost $376 a year more than albuterol alone in this study, $454 a year per patient is saved on extra outpatient visits, medications, and hospitalization costs, for an overall saving of $78 a year per patient. This cost savings is an underestimate of the true cost effectiveness of ICs, as it does not take into account testing and radiographs during the hospitalizations or the savings in indirect costs.
33. Barnes PJ: Inhaled glucocorticoids for asthma. N Engl J Med 1995, 332:868-875.
34. Baraniuk J: Steroids in asthma: molecular mechanisms of glucocorticoid actions. J Allergy Clin Immunol 1996, 97(1 pt 2):141-182.
35. McCubbin M, Milavetz G, Grandgeorge S, Weinberger M, Ahrens R, Sargent C, Vaughn L: A bioassay for topical and systemic effects of three inhaled corticosteroids. Clin Pharmacol Ther 1995, 57:455-460. Many comparative studies of IC preparations compare an equal number of puffs of canisters delivering different doses per actuation or compare inhaled medications delivered in different manners. This is one of a few studies comparing medications over a full dosing range (400 to 4000 μg/d) on a microgram-to-microgram basis. For any given dose, BDP, triamcinolone acetonide, and fluticasone propionate were equivalent in their dose-dependent ability to reduce sensitivity to antigen inhalation challenge and in their capacity to reduce urinary free cortisol.
36. Eseverri J, Botey J, Marin A: Budesonide: treatment of bronchial asthma during childhood. Allerg Immunol (Paris) 1995, 27:129-135.
37. Noonan M, Chervinsky P, Busse W, Weisberg S, Pinnas J, de Boisblanc B, Boltansky H, Pearlman D, Repsher L, Kellermen D: Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995, 152:1467-1473.
38. Robinson D, Geddes D: Inhaled corticosteroids: benefits and risks. J Asthma 1996, 33:5-16. This recent review of the risks and benefits of ICs appropriately points out that the clinical relevance of the measured adverse effects is not known and that the risk of poorly controlled asthma is probably a greater concern.
39. Larson B, Dahl R: Do inhaled steroids have similar efficacy? A case of branchial asthma suggesting different efficacy of inhaled glucocorticosteroids. Allergy 1995, 50:600-603.
40. Doull I, Freezer N, Holgate S: Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995, 151:1715-1719. After 7 months, children treated with BDP, 200 mg/d, grew 1 cm less than placebo-treated children. During the 4 months following therapy, the BDP and placebo groups grew at the same rate, but the BDP group failed to demonstrate any catch-up growth.
41. Crowley S, Hindmarsh P, Matthews D, Brook C: Growth and growth hormone axis in prepubertal children with asthma. J Pediatr 1995, 126:297-303.
42. Volovitz B, Amir J, Malik H, Kauschansky A, Varsano I: Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide. N Engl J Med 1993, 329:1703-1708.
43. Ninan T, Russell G: Asthma, inhaled corticosteroid treatment, and growth. Arch Dis Child 1992, 67:703-705.
44. Hanania N, Chapman K, Sturtridge W, Szalai J, Kesten S: Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 1995, 96(5 pt 1):571-579.
45. Birkebaek N, Esberg G, Andersen K, Wolthers O, Hassager C: Bone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate. Arch Dis Child 1995, 73:524-527.
46. Martinati L, Bertoldo F, Gasperi E, Micelli S, Boner A: Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with asthma. Am J Respir Crit Care Med 1996, 153:232-236.
47. Toogood J, Baskerville J, Markov A, Hodsman A, Fraher L, Jennings B, Haddad R, Drost D: Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995, 96:157-166.
48. Le Bourgeois M, Cormier C, Kindermans C, Souberbielle J, Garabedian M, de Blic J, Scheinmann P: Inhaled beclomethasone and bone metabolism in young children: a six month study. J Allergy Clin Immunol 1995, 96:565-567.
49. Hopp R, Degan J, Biven R, Kinberg K, Gallagher G: Longitudinal assessment of bone mineral density in children with chronic asthma. Ann Allergy Asthma Immunol 1995, 75:143-148. Twenty-one asthmatic children (mostly prepubertal) were treated with low- or mid-dose inhaled BDP with a spacer device for 7 to 16 months. Bone densitometry was measured twice and compared with normal curves developed by measuring bone density on 107 normal children. The study group demonstrated an increase in bone density as expected with age.
50. Clark D, Grove A, Cargill R, Lipworth B: Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996, 51:262-266.
51. Volovitz B, Kauschansky A, Nussinovitch M, Harel L, Varsano I: Normal diurnal variation in serum cortisol concentration in asthmatic children treated with inhaled budesonide. J Allergy Clin Immunol 1995, 96:874-877.
52. Goldberg S, Algur A, Levi M, Brukheimer E, Hirsch H, Branski D, Kerem E: Adrenal suppression among asthmatic children receiving chronic therapy with inhaled corticosteroid with and without a spacer device. Ann Allergy Asthma Immunol 1996, 76:234-238. The benefits of spacer devices to enhance drug delivery are well known. In this paper, the authors demonstrate that spacer use is associated with a decreased risk for reduction in urinary free cortisol excretion. Forty-seven percent of patients using a metered-dose inhaler without a spacer had reduced excretion as compared with 8% of those who used a spacer. As a whole, the former group's 24-hour urinary free cortisol excretion was significantly less than that of the spacer or nontreated control groups. The spacer group did not differ from the control group.
53. Asmus M, Teresi M, Milavetz G, Ahrens R: How will the CFC ban affect MDIs. J Respir Dis 1996, 17:34-37.
54. Byron P: Inhalation devices. In The Pharmacy and Pharmacotherapy of Asthma. Edited by D'Arcy P, McElnay J. Chichester, UK: Ellis Horwood; 1989, 137-159.
55. Leflein J, Brown E, Hill M, Kelly H, Loffert D, Nelson H, Szefler S: Delivery of glucocorticoids by jet nebulization: Aerosol characteristics and output. J Allergy Clin Immunol 1995, 95:944-949.
56. FDA Medical Bulletin. Food and Drug Administration; 1991: 21:3.
57. American Academy of Allergy, Asthma, and Immunology: Position statement: inhaled corticosteroids and severe viral infections. J Allergy Clin Immunol 1993, 92:223-228.
58. Levy J, Zalkinder I, Kuperman O, Skibin A, Apte R, Bearman J, Mileke P, Tal A: Effect of prolonged use of inhaled steroids on the cellular immunity of children with asthma. J Allergy Clin Immunol 1995, 95:806-812.
59. van Schoor J, Toogood J, Pauwels R: Short courses of high dose inhaled budesonide and serum IgG subclass levels in healthy volunteers. J Allergy Clin Immunol 1996, 97:113-118.
60. Sy M, Chin T, Nussbaum E: Pneumocystis carinil pnumonia associated with inhaled corticosteroids in an immunocompetent child with asthma. J Pediatr 1995, 127:1000-1002. Although no one has demonstrated significant effects of ICs on immunity, case reports such as this raise the possibility that isolated rare events occur. Infrequent abnormalities may not cause statistical significance in large studies.
61. Nelson H: β-Adrenergic bronchodilators. N Engl J Med 1995, 333:499-506. This excellent review describes the role of β-agonists in asthma management and the potential risks of regular use.
62. Barnes PJ: β-Adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995, 152:838-860.
63. Spitzer W, Suissa S, Ernst P, Horwitz R, Habbick B, Cockroft D, Boivin J, McNutt M, Buist A, Rebuck A: The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992, 326:501-506.
64. Pearce N, Beaseley R, Crane J, Burgess C, Jackson R: End of the New Zealand asthma mortality epidemic. Lancet 1995, 345:41-44.
65. Grove A, Lipworth B: Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995, 346:201-206.
66. Cockroft D, O'Byrne P, Swystun V, Bhagat R: Regular use of inhaled albuterol and the allergen-induced late phase response. J Allergy Clin Immunol 1995, 96:44-49. Demonstrates increased late-phase responses after antigen challenge in the regularly treated group. The late airway response is an inflammatory phase and as such may account for the increased reactivity to methacholine observed in another study (Bhagat et al., J Allergy Clin Immunol 1996, 97:47-52).
67. Bhagat R, Swystun V, Cockroft D: Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: Dose response. J Allergy Clin Immunol 1996, 97:47-52. This placebo-controlled study indicates that regular use of β-agonists may be associated with increased bronchial reactivity to nonspecific and specific triggers of asthma.
68. Tilles S, Nelson H: Long-acting inhaled β agonists. J Asthma 1995, 32:387-404.
69. Lockey R: Adverse reactions associated with skin testing and immunotherapy. Allergy Proc 1995, 16:293-296.
70. Creticos P, Reed C, Norman P, Khoury J, Adkinson N, Buncher R, Busse W, Bush R, Gadde J, Li J, et al.: Ragweed immunotherapy in adult asthma. N Engl J Med 1996, 334:501-506.
71. Abramson M, Puy R, Weiner J: Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995, 151:969-974. In a statistically complex study, the authors prove that the preponderance of the evidence supports immunotherapy as an effective therapy for asthma.
72. Sigman K, Mazer B: Immunotherapy for childhood asthma: is there a rationale for its use. Ann Allergy Asthma Immunol 1996, 76:299-309.
73. Spector S: Leukotriene inhibitors and antagonists in asthma. Ann Allergy Asthma Immunol 1995, 75:463-474. The 5-lipoxygenase inhibitors and the leukotriene antagonists may be the next new classes of anti-asthma drugs to become available. This comprehensive review summarizes studies done in the their development.
74. Wenzel S, Trudeau J, Kaminsky D, Cohn J, Martin R, Westcott J: Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995, 152:897-905.
75. Fischer A, McFadden C, Frantz R, Awni W, Cohn J, Drazen J, Israel E: Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthma subjects. Am J Respir Crit are Med 1995, 152:1203-1207.
76. Israel E, Cohn J, Dube L, Drazen J: Effect of treatment with Zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA 1996, 275:931-936.
77. Ohman J, Bennett D, Happ M, Settles M, Jones N, Hirani S, Long A: The cat room model for associating allergen levels with asthma symptoms and evaluating treatment effects of peptide therapy [abstract 817]. J Allergy Clin Immunol 1996, 97(1 pt 3):387.
78. Bleeker E, Bousquet J, Frie M, Holgate S, Meyers D, Morton N: Recent advances in the genetics of asthma and allergies: report of a symposium held in Cannes, France, 28 September-1 October 1994. Clin Exp Allergy 1995, 25(suppl 2):1-125.
79. Donovan G, Manolios N, Weiner J, Grennan D, Huang Q, Dunckley H, Baldo B: A family study of allergy: segregation with HLA, but not with T-cell receptor genes. J Allergy Clin Immunol 1996, 97:712-713.
80. Postma D, Bleecker E, Amelung P, Holroyd K, Xu J, Panhuysen C, Meyers D, Levitt RC: Genetic susceptibility to asthma: bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med 1995, 333:894-900. News of the asthma gene was abundant in the lay press. This fascinating research may ultimately prove to be of clinical and therapeutic relevance.
81. Meltzer E: An overview of current pharmacotherapy in perennial rhinitis. J Allergy Clin Immunol 1995, 95:1097-1110.
82. 1 blockers. Here she demonstrates the poor correlation between subjective (somnolence) and objective (reaction time) effects of antihistamines. In addition, the effects of one antihistamine did not predict the effects of another, justifying the prescribing practice of trying a second antihistamine if there are unacceptable adverse effects from the first.
83. Carlston J: Drug interactions and cytochrome P-450 enzymes. Ped Asthma Allergy Immunol 1995, 9:123-132.
84. Pinney S, Koller B, Franz M, Woolsey R: Terfenadine increases the QT interval in isolated guinea pig heart. J Cardiovasc Pharmacol 1995, 25:30-34.
85. Hanrahan J, Choo P, Carlson W, Greineder D, Faich G, Platt R: Terfenadine associated ventricular arrhythmias and QTc prolongation. Ann Epidemiol 1995, 5:201-209. Because second-generation antihistamine and macrolide antibiotics are so frequently prescribed, we have become aware of relatively uncommon, but potentially fatal, adverse effects of their concomitant use. Nonetheless, the risk of a serious cardiac event is real, and simultaneous administration of erythromycin and antihistamines, especially terfenadine, is not recommended.
86. Storms W: Treatment of seasonal allergic rhinitis with fluticasone propionate aqueous nasal spray: Review of comparator studies. Allergy 1995, 50(suppl 23):25-29.
87. Boner A, Sette L, Martinati L, Sharma R, Richards D: The efficacy and tolerabllity of fluticasone propionate aqueous nasal spray in children with seasonal allergic rhinitis. Allergy 1995, 50:498-505.
88. Kaiser H, Findlay S, Georgitis J, Grossman J, Ratner P, Tinkelman D, Roszko P, Zegarelli E, Wood C: Long-term treatment of perennial allergic rhinitis with ipratropium nasal spray 0.06%. J Allergy Clin Immunol 1995, 95:1128-1132.
89. Friedlaender M: Management of ocular allergy. Ann Allergy Asthma Immunol 1995, 75:212-224. Allergic conjunctivitis often gets little respect in the spectrum of allergic disorders, but it and related disorders can result in serious ocular damage. This up-to-date review differentiates the features of ocular allergic disorders and describes the role of newer ophthalmic solutions in their treatment.
90. Alexander M: Comparative therapeutic studies with Tilavist. Allergy 1995, 50(suppl 21):23-29.
91. Louhiala P, Jaakkola N, Ruotsalainen R, Jaakkola J: Form of day care and respiratory infections among Finnish children. Am J Public Health 1995, 85:1109-1112.
92. Noah T, Henderson F, Wortman I, Devlin R, Handy J, Koren H, Becker S: Nasal cytokine production in viral acute upper respiratory infection of childhood. J Infect Dis 1995, 171:584-592.
93. Johnston S, Pattemore P, Sanderson G, Smith S, Lampe F, Josephs L, Symington P, O'Toole S, Myint S, Tyrrell D, Holgate S: Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995, 310:1225-1228. Over 100 children ages 9 to 11 were monitored for 13 months using diary card respiratory symptom and peak expiratory monitoring. Parents telephoned when symptoms occurred and specimens were obtained for viral analysis. Viruses were reported in 85% of episodes of upper respiratory symptoms, cough, wheeze, and fall in peak expiratory flow rate.
94. Busse W: Viral infections in humans. Am J Respir Crit Care Med 1995, 151:1675-1677.
95. Diamond L, Dockhorn R, Grossman J, Kisicki J, Posner M, Zinny M, Koker P, Korts D, Wecker M: A dose-response study of the efficacy and safety of ipratropium bromide naseal spray in the treatment of the common cold. J Allergy Clin Immunol 1995, 95:1139-1146.